Comparative Study of Tranexamic Acid, Estrogen for Treatment AUB in DMPA Users

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-30

Study Completion Date

2024-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Abnormal uterine bleeding is the most common problems to discontinue Depo-medroxyprogesterone acetate (DMPA) in Thailand. This clinical trial use to provide drug to stop abnormal uterine bleeding from DMPA

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding

NCT01148420

Dysfunctional Uterine Bleeding

COMPLETED PHASE4

Efficacy of Cyclic DSG Compared With Cyclic MPA for the Treatment of Anovulatory DUB

NCT02103764

Dysfunctional Uterine Bleeding

UNKNOWN PHASE3

Efficacy and Safety,Long-term Study of Low-dose Oral Contraceptive Pill to Treat Dysmenorrhea.

NCT00212277

Dysmenorrhea

COMPLETED PHASE3

Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study

NCT01428713

Menorrhagia

COMPLETED NA

Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial

NCT00350480

Uterine Hemorrhage Menorrhagia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Abnormal uterine bleeding is the most common problems to discontinue Depo-medroxyprogesterone acetate (DMPA) in Thailand. After discontinue DMPA, patients have not used any method. Unwanted pregnancy are rising. The reason of abnormal uterine bleeding from DMPA aren't clearly understand. In present, no standard treatment to treat abnormal utrerine bleeding in DMPA users.This clinical trial use to provide drug to stop abnormal uterine bleeding from DMPA with minimal dose and minimal side effect

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abnormal Uterine Bleeding Tranexamic Acid Estrogen Depot Medroxyprogesterone Acetate

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Drug in concealed envelop which participant and care provider aren't see

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tranexamic acid

Tranexamic acid 250 mg oral three times/day

Group Type EXPERIMENTAL

Tranexamic acid 250 mg oral tablet

Intervention Type DRUG

Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users

Progynova

Progynova 1 mg oral three times/day

Group Type EXPERIMENTAL

Progynova 1 mg oral tablet

Intervention Type DRUG

Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tranexamic acid 250 mg oral tablet

Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users

Intervention Type DRUG

Progynova 1 mg oral tablet

Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Abnormal uterine bleeding more than 7 days after first DMPA injection
* Provide inform consent with patient
* Can understand thai language

Exclusion Criteria

* Have contraindication to use Tranexamic acid and estrogen such as hypertension, Stroke, MI, DM, Renal disease, Liver disease, CA breast etc.
* Have pathology in uterus from pelvic examination, pap smear and ultrasound
* Current pelvic infection
* Postpartum less than 6 months
* History deep vein thrombosis
* Breastfeeding

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes